The hyperactivation of PAK1 in cutaneous melanomas may be further attributed to activating mutations in RAC1 [47,48], but also to even more common activating mutations in NRAS and the inactivation of RAS inhibitor NF1 [47], as RAS-induced transformation involves and depends on the activation of RAC1 and PAK1 [49,50,51,52]. This evidence concerns the gene PAK1 and cutaneous melanoma.